GSK reports results from Phase III trials of drug candidate for severe asthma
In the trials, depemokimab showed an ability to significantly reduce severe asthma exacerbations.
10 September 2024
10 September 2024
In the trials, depemokimab showed an ability to significantly reduce severe asthma exacerbations.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.